Skip to main content

Study results disappoint for Vascular Biogenics

Vascular Biogenics Ltd. (Nasdaq: VBLT) reported disappointing results from a Phase 3 GLOBE study in patients with recurrent glioblastoma sending the stock price plummeting $4.15 to close at $2.65.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.